




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

Jaroslav A. Hubacek^{a,*}, Ladislav Dusek^{b,c}, Ondrej Majek^{b,c}, Vaclav Adamek^d,
Tereza Cervinkova^e, Dana Dlouha^a, Vera Adamkova^{d,e}

^a Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, Czech Republic

^b Institute of Health Information and Statistics of the Czech Republic, Palackeho namesti 4, Prague, Czech Republic

^c Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice753/5, Brno, Czech Republic

^d Czech Technical University, Faculty of Biomedical Engineering, Sitná 3105, Kladno, Czech Republic

^e Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, Czech Republic

ARTICLE INFO

Keywords:

COVID-19
ACE
Polymorphism
Insertion/deletion

ABSTRACT

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality.

Methods: In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects.

Results: The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; $P = 0.02$; OR [95% CI] = 1.55 [1.17–2.05]). Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; $P = 0.002$; OR [95% CI] = 1.78 [1.22–2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients ($P = 0.76$).

Conclusions: We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID-19, with I/I homozygotes being at increased risk of symptomatic COVID-19.

1. Introduction

Infection by SARS-CoV-2 represents a new emerging healthy situation around the globe. The infection emerged in China probably at the end of 2019 and rapidly spread to all continents. The novel virus named SARS coronavirus 2 (SARS-CoV-2) [1] is associated with the pneumonia-associated disease known as COVID-19 (CoronaVirus Disease – 2019). In contrast to other coronavirus-associated diseases (SARS, MERS), COVID-19 is a far milder upper respiratory tract illness but has superior transmission capability [2,3].

Very quickly, it has been recognized that there are significant geographical and interethnic variations in COVID-19 prevalence [2,4,5] and COVID-19-associated mortality. The variability in the host immune system [6,7] caused by genetic background might partly explain the described prevalence differences.

Among the candidates with the potential to affect SARS-CoV-2 infection and COVID-19 symptoms and severity, the ACE gene is often

mentioned and has been extensively examined in several studies (for example, see [8–10]).

ACE (angiotensin I-converting enzyme, alias kininase II; OMIM acc. No. 106180) is an important part of the renin–angiotensin–aldosterone system (RAAS). ACE2, another member of the RAAS family, is recognized as a gateway for SARS-CoV-2 particle entry into cells, serving as their receptor [11]. However, variants within ACE2 were not associated with the prevalence or severity of SARS during the 2003/2004 outbreak [12].

Within the Alu sequence of intron 16 of the ACE gene, there is a functional polymorphism, represented by an insertion/deletion (I/D) of 287 bp (rs4646994). The D allele is significantly associated with increased activity and concentration of the enzyme [13], but associations with blood pressure or with increased cardiovascular risk were found in some but not in all studies (summarized by [14–16]).

Insertion/deletion ACE polymorphisms exhibit some significant geographical and ethnic variability, where the frequency of the I allele

* Corresponding author at: IKEM-EMC, Videnska 1958/9, 14021 Prague 4, Czech Republic.

E-mail address: jahb@ikem.cz (J.A. Hubacek).

<https://doi.org/10.1016/j.cca.2021.04.024>

Received 27 April 2021; Received in revised form 29 April 2021; Accepted 29 April 2021

Available online 3 May 2021

0009-8981/© 2021 Elsevier B.V. All rights reserved.

is increased in Asian and African populations in comparison to that in Caucasians.

As a detailed analysis of the COVID-19 course and I/D *ACE* polymorphism has not yet been performed, our study focused on analysis of the I/D polymorphism within the *ACE* gene in symptomatic and asymptomatic SARS-CoV-2-positive patients from the first COVID-19 wave in the Czech Republic.

2. Material and methods

2.1. Subjects

The *ACE* I/D polymorphism was genotyped in 410 COVID-19 subjects (Table 1) who tested positive for the presence of SARS-CoV-2 infection (and completely recovered at the time of sample collection – July 2020) during the first wave (app. March 2020 – June 2020) of the disease in the Czech Republic [17]. Of them, 164 were asymptomatic, and 246 were symptomatic (without hospitalization).

As controls, 2,559 adults were used (post-MONICA study [18,19]; random 1% population sample from 9 districts, stratified by age and sex). Their *ACE* genotypes were known from a previous study [20].

Written informed consent was provided by all subjects involved in the study. The study protocol was approved by the institutional ethics committee.

2.2. DNA analysis

DNA was isolated from EDTA-treated blood [21]. The *ACE* I/D polymorphism was genotyped as described in detail by Rigat et al. [22]. PCR products of ~ 490 bp and ~ 200 bp characterise the I and D alleles, respectively. All D/D subjects were re-genotyped with *ACE* I-specific oligonucleotides according to Ueda et al. [23] to avoid the mis-genotyping of some I/D heterozygotes as D/D homozygotes. Based on confirmatory genotyping, 51 (3.8%) controls and 4 (0.9%) patients primarily genotyped as D/D were reclassified as I/D. PCR was performed on an MJ Research DYAD Disciple PCR device (MJ Research, MA, US), and all chemicals were produced by Fermentas International Inc. (Burlington, Ontario, Canada).

2.3. Statistical analysis

Statistical analysis has been performed using the www.socscistatistics.com tools (accessed 12/2020).

3. Results

The achieved call rate was 99.5% for COVID-19 patients and 98.2% for controls. In both the patient and control groups, the genotype frequencies were in agreement with Hardy-Weinberg equilibrium.

We observed significant differences in genotype frequencies of the *ACE* I/D polymorphisms between the patients and controls (for additional details, see Table 2).

The frequency of *ACE* I/I homozygotes was significantly increased in the entire group of COVID-19 patients compared with that in the controls (26.2% vs. 21.2%; $P = 0.02$; OR [95% CI] = 1.55 [1.17–2.05] for I/I vs. + D comparison).

Table 1

General characteristics of controls and COVID-19-positive subjects.

	Controls	Patients
N	2,579	410
Age (years)	48 ± 11	44 ± 15
% female	53.4	54.7
Diabetes (%)	8.2	7.8
Hypertension (%)	22.3	13.3

Importantly, however, the difference was driven by the symptomatic subjects only (29.0% vs. 21.2% of I/I homozygotes; $P = 0.005$; OR [95% CI] = 1.51 [1.13–2.02] for I/I vs + D comparison; $P = 0.0025$; OR [95% CI] = 1.78 [1.22–2.60] for D/D vs. I/I comparison).

The genotype distribution of the *ACE* genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients ($P = 0.79$; OR [95% CI] 1.05 [0.72–1.54]; for additional details, see Table 2).

4. Discussion

In our study, we detected a significant effect of the *ACE* insertion/deletion polymorphism on the risk of symptomatic SARS-CoV-2 infection/COVID-19.

The I/D polymorphism within the *ACE* gene is among the heavily discussed inherited variants with the potential to influence the COVID-19 outcome [8,10,24,25], but especially as papers mostly have no direct patient data the conclusions are not uniform but rather contradictory. Some papers are suggesting the D allele and others suggesting the I allele as deleterious.

Mostly, the ecological studies used mortality data from different dates, which could lead to misreporting as the pandemic has different course due to time in different countries. Further, there are important regional differences in spread of pandemic within the countries and finally, for identical countries, different I/D ratios and different models (dominant or recessive) were used for calculation.

For example, our results are in agreement with the results described by Delanghe et al. [8,26]. They compared the numbers of fatalities, related both per million inhabitants and per number of total cases, within the first COVID-19 wave in data from dozens of European countries and recognized the I/I genotype as deleterious.

The functional link between *ACE* I/D polymorphism and infectivity and pathogenicity of the SARS-Cov-2 virus has been recently proved by Jacobs et al. [27]. In I/I homozygotes, increased ACE2 protein levels in lung epithelium has been detected – this can facilitate the virus entry into the host organism as ACE2 is used by the virus as gateway for cell entry.

Studies performed on Asian populations [24,28,29], reported opposite results and suggested a D/D genotype as a predictive marker of COVID-19 severity. These discrepancies could be caused by the fact, that there could be ethnicity specific allelic effect similar to the effect of response on ACE inhibitor treatment (see below, [30]). Different conclusions reached are indirectly confirmed by the fact that some nonwhite ethnicities with increased COVID-19 mortality exhibit an increased population frequency of the I allele.

However, the studies are very difficult to compare. The major difference between our and these studies is in the protocol performed. Furthermore, these studies have generally extrapolated the available data about the *ACE* I/D genotype frequencies and publicly available data about the prevalence of the disease. In contrast to the abovementioned studies, we have direct access to the patient DNA, COVID –19 status and we have the possibility to compare the *ACE* genotype frequencies directly with the large and population based sample. The abovementioned studies focused on mortality cases, which is in contrast with our study, which is focused on survivors and compares symptomatic and asymptomatic subjects. In contrast, we focused on concrete subjects, individuals who tested positive for suffering from SARS-CoV-2 infection, and linked the exact genotype with disease symptoms. Despite these differences, we have obtained similar results.

Importantly, a large cohort study performed in England detected that ACE inhibitor treatment was associated with a significantly (with a HR of approximately 0.7) reduced risk of COVID-19 [30], even after multiple adjustments. Furthermore, it cannot be excluded that the *ACE* I/D polymorphism could play different roles in different stages of infection and disease as well as in different ethnicities, as ACE inhibitors seem to be protective against COVID-19 in white UK subjects but in contrast

Table 2

Distribution of the ACE rs4646994 I/D polymorphism within the control and COVID-19-positive subject groups.

ACE	Controls		COVID-19 asymptomatic		COVID-19 symptomatic		OR Controls vs. asymptomatic	P	P*	OR Controls vs. symptomatic	P	P*
	N	%	N	%	N	%						
I/I	547	21.2	36	22.1	71	29.0	1.15 (0.72–1.83)	0.55	0.46*	1.78 (1.22–2.60)	0.002	0.03*
I/D	1331	51.6	87	53.4	123	50.2	1.14 (0.79–1.68)	0.49	0.76#	1.27 (0.91–1.78)	0.16	0.008#
D/D	701	27.2	40	24.5	51	20.8	1.00		0.98§	1.00		0.005§
I/I	547	21.2	36	22.1	71	29.0	1.05 (0.72–1.54)	0.79		1.51 (1.13–2.02)	0.005	
+D	2032	78.8	127	77.9	174	71.0	1.00			1.00		
+I	1878	72.8	123	75.5	194	79.2	1.14 (0.80–1.66)	0.46		1.42 (1.03–1.96)	0.03	
D/D	701	27.2	40	24.5	51	20.8	1.00			1.00		

P* for D/D vs. + I*; D/D vs. I/D vs. I/I#, +D vs. I/I§ comparisons.

even deleterious in nonwhite UK subjects. It would be of interest to study whether there is some interaction between ACE genotypes and ACE inhibitors in susceptibility to symptomatic COVID-19.

Among other factors, male sex, obesity, diabetes and nonwhite ethnicity are reported to be associated with an increased risk of COVID-19 [4]. Within the control group, we did not detect any association between the ACE I/D polymorphism and blood pressure, body mass index or the presence of diabetes mellitus, suggesting a context-independent association with disease.

The possibility of predicting symptomatic COVID-19 using a simple, quick and inexpensive test based on individual subject DNA polymorphisms could be very important in general testing to distinguish between subjects with high and low risk of disease and, importantly, for the estimation of the severity of the disease. It is certain that the analysis of one polymorphism will not be sufficient, and the examination of a wide list of polymorphisms will be necessary. Creation of the genetic risk score reflecting the host ability to affect the individual's sensitivity to COVID-19 could be important.

The COVID situation has evoked a wave of interest focused on potential host genetic predisposition to the disease. The list of suggested polymorphisms [6] with potential to affect SARS-CoV-2 susceptibility is long (including, for example, genes for vitamin D receptor, MBL and CLEC4M), but so far, undoubtedly confirmed and widely replicated genetic determinants of SARS-CoV-2 infection and COVID-19 severity remain unknown.

Genetic susceptibility to COVID-19 was also examined using the genome-wide association approach [31]. This study detected a few useful signals within the ABO blood-group system, suggesting a benefit in blood group O and increased risk associated with blood group A. The second strongest signal was localized at the 3p21.31 locus, where promising candidates, such as genes for two chemokine receptors, CCR9 and CXCR6, or the gene for SLC6A20, which interacts with ACE2, are localized.

Nonetheless, the differences in the prevalence of disease suggest possible nonuniversality of the involved genes/variants, as suggested by our results, where the ACE I/I genotype is associated with the symptomatic course of the disease.

5. Conclusion

The results of our study suggest that ACE I/I homozygotes may be at an increased risk of symptomatic COVID-19, at least in East European Caucasians.

Funding

The study was supported by Ministry of Health, Czech Republic - conceptual development of research organization (“Institute for Clinical and Experimental Medicine – IKEM, IN 00023001”).

CRedit authorship contribution statement

Jaroslav A. Hubacek: Conceptualization, Formal analysis, Funding acquisition, Project administration, Writing - original draft. **Ladislav Dusek:** Conceptualization, Funding acquisition, Project administration, Supervision, Writing - review & editing. **Ondrej Majek:** Formal analysis, Investigation, Supervision, Writing - review & editing. **Vaclav Adamek:** . **Tereza Cervinkova:** Data curation, Investigation, Writing - review & editing. **Dana Dlouha:** Writing - review & editing, Investigation, Methodology, Writing - review & editing. **Vera Adamkova:** Conceptualization, Data curation, Funding acquisition, Project administration, Supervision, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

- [1] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat. Microbiol.* 5 (2020) 536–44. <https://doi.org/10.1038/s41564-020-0695-z>.
- [2] K. Dhama, S. Khan, R. Tiwari, S. Sircar, S. Bhat, Y.S. Malik, K.P. Singh, W. Chaicumpa, D.K. Bonilla-Aldana, A.J. Rodriguez-Morales, Coronavirus Disease 2019-COVID-19, *Clin. Microbiol. Rev.* 33 (2020), e00028-20, <https://doi.org/10.1128/CMR.00028-20>.
- [3] M.M. Berekaa, *Insights into the COVID-19 pandemic: Origine, pathogenesis, diagnosis, and therapeutic interventions*, *Front. Biosci. (Elite Ed)* 13 (2021) 117–139.
- [4] C.E. Hastie, D.F. Mackay, F. Ho, C.A. Celis-Morales, S.V. Katikireddi, C.L. Niedzwiedz, B.D. Jani, P. Welsh, F.S. Mair, S.R. Gray, C.A. O'Donnell, J.M. Gill, N. Sattar, J.P. Pell. Vitamin D concentrations and COVID-19 infection in UK Biobank. *Diabetes Metab. Syndr.* 14 (2020) 561–5. Erratum. In: *Diabetes Metab Syndr.* 2020; 14:1315–1316. <https://doi.org/10.1016/j.dsx.2020.04.050>.
- [5] Z. Raisi-Estabragh, C. McCracken, M.S. Bethell, J. Cooper, C. Cooper, M. J. Caulfield, P.B. Munroe, N.C. Harvey, S.E. Petersen, Greater risk of severe COVID-19 in Black, Asian and minority ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank, *J. Public Health (Oxf)* 42 (2020) 451–460, <https://doi.org/10.1093/pubmed/fdaa095>.
- [6] E. Di Maria, A. Latini, P. Borgiani, G. Novelli, Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis, *Hum. Genomics.* 1430 (2020), <https://doi.org/10.1186/s40246-020-00280-6>.
- [7] I.G. Ovsyannikova, I.H. Haralambieva, S.N. Crooke, G.A. Poland, R.B. Kennedy, The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity, *Immunol. Rev.* 296 (2020) 205–219, <https://doi.org/10.1111/imr.12897>.
- [8] J.R. Delanghe, M.M. Speeckaert, M.L. De Buyzere, COVID-19 infections are also affected by human ACE1 D/I polymorphism, *Clin. Chem. Lab. Med.* 58 (2020) 1125–1126, <https://doi.org/10.1515/cclm-2020-0425>.
- [9] S. Mohammadpour, Esfahani A. Torshizi, M. Halaji, M. Lak, R. Ranjbar, An updated review of the association of host genetic factors with susceptibility and resistance to COVID-19, *J. Cell. Physiol.* (2020), <https://doi.org/10.1002/jcp.29868>.
- [10] M. Bellone, S.L. Calvisi, ACE polymorphism and COVID-19-related mortality in Europe, *Mol. Med. (Berl)*. 98 (2020) 1505–1509, <https://doi.org/10.1007/s00109-020-01981-0>.
- [11] M. Hoffmann, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T.S. Schiergens, G. Herrler, N.H. Wu, A. Nitsche, M.A. Müller, C. Drosten, S. Pöhlmann, SARS-CoV-

- 2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, *Cell* 181 (2020), 271–80.e8, <https://doi.org/10.1016/j.cell.2020.02.052>.
- [12] R.W. Chiu, N.L. Tang, D.S. Hui, G.T. Chung, S.S. Chim, K.C. Chan, Y.M. Sung, L. Y. Chan, Y.K. Tong, W.S. Lee, P.K. Chan, Y.M. Lo, ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome, *Clin. Chem.* 50 (2004) 1683–1686, <https://doi.org/10.1373/clinchem.2004.035436>.
- [13] F. Cambien, F. Alhenc-Gelas, B. Herbeth, J.L. Andre, R. Rakotovoao, M.F. Gonzales, J. Allegrini, C. Bloch, Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study, *Am. J. Hum. Genet.* 43 (1988) 774–780.
- [14] J.A. Hubáček, R. Poledne. [Insertion/deletion polymorphism in the gene for angiotensin-converting enzyme and cardiovascular disease]. *Cor Vasa.* 41 (1999) 149–54. Article in Czech.
- [15] B. Agerholm-Larsen, B.G. Nordestgaard, A. Tybjaerg-Hansen, ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites, *Arterioscler. Thromb. Vasc. Biol.* 20 (2000) 484–492, <https://doi.org/10.1161/01.atv.20.2.484>.
- [16] B. Mayer, H. Schunkert, ACE-Gen-Polymorphismus und kardiovaskuläre Erkrankungen [ACE gene polymorphism and cardiovascular diseases]. *Herz.* 25 (2000) 1–6. Article in German. <https://doi.org/10.1007/BF03044118>.
- [17] J.A. Hubacek, L. Dusek, O. Majek, V. Adamek, T. Cervinkova, D. Dlouha, J. Pavel, V. Adamkova, CCR5Δ32 deletion as a protective factor in Czech first-wave COVID-19 subjects, *Physiol. Res.* 70 (2021) 111–115, <https://doi.org/10.33549/physiolres.934647>.
- [18] R. Cífková, Z. Skodová, J. Bruthans, V. Adámková, M. Jozífová, M. Galovcová, P. Wohlfahrt, A. Krajcoviechová, R. Poledne, P. Stávek, Lánská V. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA, *Atherosclerosis* 211 (2010) 676–681, <https://doi.org/10.1016/j.atherosclerosis.2010.04.007>.
- [19] J.A. Hubacek, V. Stanek, M. Gebauerová, A. Pilipincová, D. Dlouhá, R. Poledne, M. Aschermann, H. Skalická, J. Matousková, A. Kruger, M. Penicka, H. Hrabáková, J. Veselka, P. Hájek, V. Lánská, V. Adámková, J. Pitha, A FTO variant and risk of acute coronary syndrome, *Clin. Chim. Acta* 411 (2010) 1069–1072, <https://doi.org/10.1016/j.cca.2010.03.037>.
- [20] J.A. Hubacek, J. Pitha, I. Podrapská, J. Sochman, V. Adámková, V. Lánská, R. Poledne, Insertion/deletion polymorphism in the angiotensin-converting enzyme gene in myocardial infarction survivors, *Med. Sci. Monit.* 6 (2000) 503–506.
- [21] S.A. Miller, D.D. Dykes, H.F. Polesky, A simple salting out procedure for DNA extraction from human nucleated cells, *Nucleic Acid Res.* 16 (1988) 1215, <https://doi.org/10.1093/nar/16.3.1215>.
- [22] B. Rigat, C. Hubert, P. Corvol, F. Soubrier, PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1), *Nucleic Acids Res.* 20 (1992) 1433, <https://doi.org/10.1093/nar/20.6.1433-a>.
- [23] S. Ueda, R.P. Heeley, K.R. Lees, H.L. Elliott, J.M. Connell, Mistyping of the human angiotensin-converting enzyme gene polymorphism: frequency, causes and possible methods to avoid errors in typing, *J. Mol. Endocrinol.* 17 (1996) 27–30, <https://doi.org/10.1677/jme.0.0170027>.
- [24] N. Yamamoto, Y. Ariumi, N. Nishida, R. Yamamoto, G. Bauer, T. Gojobori, K. Shimotohno, M. Mizokami, SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype, *Gene* 758 (2020), 144944, <https://doi.org/10.1016/j.gene.2020.144944>.
- [25] M. Saadat, No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection, *Clin. Chem. Lab. Med.* 58 (2020) 1127–1128, <https://doi.org/10.1515/ccim-2020-0577>.
- [26] J.R. Delanghe, M.M. Speeckaert, M.L. De Buyzere, The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections, *Clin. Chim. Acta* 505 (2020) 192–193, <https://doi.org/10.1016/j.cca.2020.03.031>.
- [27] M. Jacobs, L. Lahousse, H.P. Van Eeckhoutte, S.R.A. Wijnant, J.R. Delanghe, G. G. Brusselle, K.R. Bracke, Effect of ACE1 polymorphism rs1799752 on protein levels of ACE2, the SARS-CoV-2 entry receptor, in alveolar lung epithelium, *ERJ. Open. Res.* 7 (2021) 00940–2020, <https://doi.org/10.1183/23120541.00940-2020>.
- [28] S. Verma, M. Abbas, S. Verma, F.H. Khan, S.T. Raza, Z. Siddiqi, I. Ahmad, F. Mahdi, Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients, *Infect. Genet. Evol.* 91 (2021), 104801, <https://doi.org/10.1016/j.meegid.2021.104801>.
- [29] H. Pati, S. Mahto, A.K. Panda Padhi, ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: An epidemiological study in the Asian population, *Clin. Chim. Acta* 510 (2020) 455–458, <https://doi.org/10.1016/j.cca.2020.08.008>.
- [30] J. Hippisley-Cox, D. Young, C. Coupland, K.M. Channon, P.S. Tan, D.A. Harrison, K. Rowan, P. Aveyard, I.D. Pavord, P.J. Watkinson, Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people, *Heart* 106 (2020) 1503–1511, <https://doi.org/10.1136/heartjnl-2020-317393>.
- [31] Severe Covid-19 GWAS Group, D. Ellinghaus, F. Degenhardt, L. Bujanda, M. Buti, A. Albillos, P. Vernizzi, J. Fernández, D. Prati, G. Baselli, R. Asselta, Genomewide association study of severe Covid-19 with respiratory failure. *N. Engl. J. Med.* 383 (2020) 1522–34. <https://doi.org/10.1056/NEJMoa2020283>.